Dimethylphenylpiperazinium

Dimethylphenylpiperazinium (DMPP) is a nicotinic acetylcholine receptor agonist which is selective for the ganglionic subtype.[1] One of the earliest reports on the pharmacology of DMPP, describing it as a ganglion-stimulating, hypertensive agent, came from Graham Chen and his co-workers at Parke, Davis & Co. (Now Pfizer)[2]

Dimethylphenylpiperazinium
Identifiers
IUPAC name
  • 1,1-Dimethyl-4-phenylpiperazin-1-ium
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H19N2
Molar mass191.298 g·mol−1
3D model (JSmol)
SMILES
  • C[N+]1(CCN(CC1)C2=CC=CC=C2)C
InChI
  • InChI=1S/C12H19N2/c1-14(2)10-8-13(9-11-14)12-6-4-3-5-7-12/h3-7H,8-11H2,1-2H3/q+1 Y
  • Key:MKGIQRNAGSSHRV-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

See also
  • Phenylpiperazine

References
  1. Prado WA, Segalla DK (August 2004). "Antinociceptive effects of bethanechol or dimethylphenylpiperazinium in models of phasic or incisional pain in rats". Brain Research. 1018 (2): 272–82. doi:10.1016/j.brainres.2004.05.085. PMID 15276888.
  2. Chen G, Portman R, Wickel A (November 1951). "Pharmacology of 1,1-dimethyl-4-phenylpiperazinium iodide, a ganglion stimulating agent". The Journal of Pharmacology and Experimental Therapeutics. 103 (3): 330–6. PMID 14898449.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.